SYNthesis BioVentures and AdAlta Collaborate to Enhance Cancer Immunotherapy

SYNthesis BioVentures and AdAlta, an Australia-based medical technology firm that specialises in the development of protein-based therapeutics, have signed a mutual agreement (MOU) to further analyse AdCella, a cancer therapeutic developed from a partnership between the two firms.  

The collaboration looks to improve cellular immunotherapies and tackle the difficulties associated with treating solid tumours.  

After the successful procurement of assets, AdAlta will possess a significant stake in AdCella, while SYNBV BioVentures will retain 25% until the subsequent funding phase.  

Tim Oldham, the head executive at AdAlta, stated, “As part of our stated strategy to expand our clinical-stage pipeline with assets that work with our i-body platform, we have identified a unique and exciting opportunity to bring highly innovative cellular immunotherapies to Australian patients.” 

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.